Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patheon Broadens Its Pharma Client Base With Mova Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Mova’s “excellent relationships with some of the largest pharmaceutical companies in the world,” including Merck, are a major attraction for Patheon, CEO Tedford says. The acquisition, valued at $350 mil., is expected to close in late December.

You may also be interested in...

FDA Warning Letter Cites Omnicef Contract Manufacturer For GMP Violations

Despite an effect on supply, Abbott said Omnicef oral suspension will remain available for patients who rely on the antibiotic.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts